Ind-Swift Laboratories per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹9.76₹4.95₹37.25₹71.24₹8.06
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹9.65₹4.84₹35.21₹71.24₹8.06
₹159.38₹159.38₹170.63₹157.64₹115.41
₹86.66₹73.85₹81.71₹216.78₹204.33
—−₹7.28−₹3.71−₹30.61₹32.94
−₹17.38−₹17.38−₹13.07−₹38.14₹30.78
8.78.76.95.95.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDSWFTLAB₹378.95

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS8.0671.2437.254.959.76
Diluted EPS8.0671.2435.214.849.65
Book Value per Share115.41157.64170.63159.38159.38
Revenue per Share204.33216.7881.7173.8586.66
Cash Flow per Share32.94-30.61-3.71-7.28—
Free Cash Flow per Share30.78-38.14-13.07-17.38-17.38
Shares Outstanding (cr)5.95.96.98.78.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.